Deducing the Conformational Properties of a Tyrosine Kinase Inhibitor in Solution by Optical Spectroscopy and Computational Chemistry

Dacomitinib (PF-00299804) was recently approved by the Food and Drug Administration (FDA) as a tyrosine kinase inhibitor (TKI). Unfortunately, side effects and disease resistance eventually result from its use. Off-target effects in some kinase inhibitors have arisen from drug conformational plastic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kabir, Md. Lutful, Backler, Frederick, Clayton, Andrew H. A., Wang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399232/
https://www.ncbi.nlm.nih.gov/pubmed/32850633
http://dx.doi.org/10.3389/fchem.2020.00596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399232/
https://www.ncbi.nlm.nih.gov/pubmed/32850633
http://dx.doi.org/10.3389/fchem.2020.00596

Ejemplares similares